Trials / Unknown
UnknownNCT05040854
Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Centro Hospitalar Tondela-Viseu · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The investigators propose an observational study including patients with inflammatory bowel disease under biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23 (Ustekinumab), followed by an external Gastroenterology consultation at Centro Hospitalar Tondela-Viseu.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | HLA-DQA1*05 and DRB1 | All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1 |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2024-04-01
- Completion
- 2024-07-01
- First posted
- 2021-09-10
- Last updated
- 2021-09-16
Locations
1 site across 1 country: Portugal
Source: ClinicalTrials.gov record NCT05040854. Inclusion in this directory is not an endorsement.